1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Advesya SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia CCTx-001 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Not yet recruiting | Advesya SAS | 143 | 2025-12-01 | 2025-09-18 |
Leukemia, Myeloid, Acute (1) · Recurrence (1)
France (1) · Germany (1) · Spain (1) · Sweden (1)